Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of First Autograft in Patients with Multiple Myeloma.

Qaiser Bashir, Peter Thall, Chitra Hosing, Floralyn L Mendoza, Eric Han, Michael Wang, M.D., Jatin Shah, MD, Amin Alousi, MD, Paolo Anderlini, Partow Kebriaei, Issa F. Khouri, Uday Popat, MD, Marcos de Lima, MD, Richard Champlin, MD, Sergio A Giralt, MD, Muzaffar H Qazilbash

Blood (2009) 114 (22): 1186.

https://doi.org/10.1182/blood.V114.22.1186.1186

Published: 2009

Journal Articles

A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.

Manish Sharma, MD, Peter Thall, PhD, Xuemei Wang, PhD, Chitra Hosing, MD, Floralyn L Mendoza, MD, Eric Han, MD, Michael Wang, MD, Donna Weber, MD, Jatin Shah, MD, Amin Alousi, MD, Paolo Anderlini, MD, Partow Kebriaei, MD, Issa F Khouri, MD, Uday Popat, MD, Marcos de Lima, MD, Richard E Champlin, MD, Sergio Giralt, MD, Muzaffar Qazilbash, MD

Blood (2009) 114 (22): 2309.

https://doi.org/10.1182/blood.V114.22.2309.2309

Published: 2009

Journal Articles

Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation.

Sofia Qureshi, MD, Manish Sharma, MD, Chitra Hosing, MD, Floralyn L Mendoza, MD, Jatin Shah, MD, Amin Alousi, MD, Paolo Anderlini, MD, Partow Kebriaei, MD, Issa F Khouri, MD, Uday Popat, MD, Marcos de Lima, MD, Richard E Champlin, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD

Blood (2009) 114 (22): 4354.

https://doi.org/10.1182/blood.V114.22.4354.4354

Published: 2009

Journal Articles

Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma

Suzanne M. Cole, MD, Rima Saliba, Matteo Pelosini, M.D., Floralyn L Mendoza, Donna Weber, MD, Michael Wang, MD, Sheeba Thomas, MD, Robert Z. Orlowski, MD, PhD, Jatin Shah, MD, Amin Alousi, MD, Chitra Hosing, MD, Uday Popat, MD, Partow Kebriaei, MD, Paolo Anderlini, MD, Issa F. Khouri, Richard Champlin, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD

Blood (2008) 112 (11): 3298.

https://doi.org/10.1182/blood.V112.11.3298.3298

Published: 2008

Journal Articles

High-Dose Topotecan, Melphalan and Cyclophosphamide (TMC) with Autologous Stem Cell Support for Multiple Myeloma

Syed MA Kazmi, MD, Floralyn L Mendoza, Donna Weber, MD, Michael L Wang, MD, Chitra Hosing, MD, Issa F. Khouri, Paolo Anderlini, Marcos De Lima, Partow Kebriaei, Uday R Popat, Richard E Champlin, MD, Sergio A Giralt, Muzaffar H. Qazilbash

Blood (2008) 112 (11): 4452.

https://doi.org/10.1182/blood.V112.11.4452.4452

Published: 2008

Journal Articles

Role of Brain-Type Natriuretic Peptide and Cardiac Troponins as Predictors of Outcome in Multiple Myeloma

Ebru Koca, Gaurav Parikh, Ali Imran Amjad, Floralyn L Mendoza, Chitra M Hosing, Uday Popat, Richard E Champlin, Sergio Giralt, Muzaffar H. Qazilbash

Blood (2008) 112 (11): 4457.

https://doi.org/10.1182/blood.V112.11.4457.4457

Published: 2008

Journal Articles

A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma

Muzaffar H. Qazilbash, Rima M. Saliba, Matteo Pelosini, M.D., Chitra M Hosing, Floralyn L Mendoza, Eric Han, Michael Wang, MD, Donna M. Weber, Amin M. Alousi, Paolo Anderlini, Partow Kebriaei, Issa F. Khouri, Uday R Popat, Marcos De Lima, Robert Z. Orlowski, MD, PhD, Richard E. Champlin, Sergio A. Giralt

Blood (2008) 112 (11): 3320.

https://doi.org/10.1182/blood.V112.11.3320.3320

Published: 2008

Journal Articles

Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.

Muzaffar H. Qazilbash, MD, Rima M. Saliba, PhD, Marilyn S. Davis, Floralyn L. Mendoza, Chitra Hosing, MD, Daniel R. Couriel, MD, Marcos De Lima, MD, Partow Kebriaei, MD, Donna M. Weber, MD, Michael Wang, MD, Amin M. Alousi, MD, Steven G. Matthes, Roy B. Jones, MD, PhD, Richard E. Champlin, MD, Sergio A. Giralt, MD

Blood (2006) 108 (11): 3090.

https://doi.org/10.1182/blood.V108.11.3090.3090

Published: 2006

NARROW

Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of First Autograft in Patients with Multiple Myeloma.

A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.

Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation.

Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma

High-Dose Topotecan, Melphalan and Cyclophosphamide (TMC) with Autologous Stem Cell Support for Multiple Myeloma

Role of Brain-Type Natriuretic Peptide and Cardiac Troponins as Predictors of Outcome in Multiple Myeloma

A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma

Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only